Small molecule · Inhibitor of beta-1,3-D-glucan synthase · developed by Glaxosmithkline
Ibrexafungerp is a triterpenoid antifungal, a semisynthetic derivative of enfumafungin, that inhibits beta-1,3-D-glucan synthase, an enzyme needed for fungal cell wall synthesis. It is studied in invasive candidiasis, aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other fungal infections.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 7, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05178862 | Phase 3 | Candidiasis, Invasive | Terminated | SCYX |
| NCT03059992 | Phase 3 | Invasive Candidiasis | Completed | SCYX |
| NCT04307082 | Phase 1 | Fungal Infection | Completed | SCYX |
| NCT04092751 | Phase 1 | Pharmacokinetics | Completed | SCYX |
| NCT04092725 | Phase 1 | Pharmacokinetics | Completed | SCYX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Allergic Bronchopulmonary AspergillosisBlastomycosisCandidemiaCandidiasis, InvasiveChronic Pulmonary AspergillosisCoccidioidomycosisFungal InfectionHistoplasmosisInvasive CandidiasisInvasive Pulmonary AspergillosisMucocutaneous CandidiasisOther Emerging FungiPharmacokineticsRecurrent Vulvovaginal Candidiasis
Updated Nov 1, 2026.